...
  • 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Anticancer Research: International Journal of Cancer Research and Treatment >Blocking Interleukin-6 and Interleukin-8 Signaling Inhibits Cell Viability, Colony-forming Activity, and Cell Migration in Human Triple-negative Breast Cancer and Pancreatic Cancer Cells
【24h】

Blocking Interleukin-6 and Interleukin-8 Signaling Inhibits Cell Viability, Colony-forming Activity, and Cell Migration in Human Triple-negative Breast Cancer and Pancreatic Cancer Cells

机译：阻断白细胞介素-6和白细胞介素-8信号传导抑制人类三阴性乳腺癌和胰腺癌细胞中的细胞活力，菌落形成活性和细胞迁移

获取原文
获取原文并翻译 | 示例
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

Background/Aim: Interleukin-6 (IL-6) and interleukin-8 (IL-8) play important roles in the progression of triple-negative breast cancer (TNBC) and pancreatic ductal adenocarcinoma (PDAC). This is the first experiment to combine small molecules targeting these two signaling pathways to treat TNBC and PDAC cells. Materials and Methods: Cell viability, colony formation and cell migration assays were conducted when TNBC or PDAC cells were treated with bazedoxifene (targeting IL-6) or reparixin/SCH527123 (targeting IL-8) or their combination. Results: The combined treatment had a more potent inhibition of cell viability, colony formation and cell migration than monotherapy in TNBC and PDAC cells. The results also showed that the combination of bazedoxifene with SCH527123 seemed to be more effective than that with reparixin in inhibiting cell viability and colony formation of TNBC. Conclusion: Novel drug combinations of bazedoxifene and reparixin, as well as bazedoxifene and SCH527123 may provide more effective treatments for TNBC and PDAC.
机译：背景/目的：白细胞介素-6（IL-6）和白细胞介素-8（IL-8）在三阴性乳腺癌（TNBC）和胰腺导管腺癌（PDAC）的进展中起重要作用。这是将靶向这两个信号传导途径的小分子组合以治疗TNBC和PDAC细胞的第一个实验。当用苯胺酰基（靶向IL-6）或Remarixin / Sch527123（靶向IL-8）或它们的组合处理TNBC或PDAC细胞时，进行细胞活力，菌落形成和细胞迁移测定。结果：该组合治疗在TNBC和PDAC细胞中的单疗法具有更有效的细胞活力，菌落形成和细胞迁移的抑制作用。结果还表明，Bazedoxifene与SCH527123的组合似乎比抑制细胞活力和TNBC的菌落形成中的remarixin更有效。结论：苯磺岛和籽粒素的新型药物组合，以及苯磺酸和苯并二氧化氮和SCH527123可为TNBC和PDAC提供更有效的处理。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号